New shot may cut bleeding episodes in Tough-to-Treat hemophilia
NCT ID NCT06312475
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 20 times
Summary
This study tests a new medicine called KN057 to see if it can prevent bleeding episodes in people with hemophilia A or B who have developed inhibitors (antibodies that block standard treatment). About 53 men aged 12 to 70 will take part. Some will get KN057 regularly for a year, while others will first receive standard on-demand treatment for 6 months before switching to KN057. The main goal is to count how many bleeding episodes occur in each group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A WITH INHIBITOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.